Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer.

Abstract:

:A fluorescence-based, high-resolution imaging approach was used to visualize longitudinally the cellular events unfolding during T cell-mediated tumor destruction. The dynamic interplay of T cells, cancer cells, cancer antigen loss variants, and stromal cells-all color-coded in vivo-was analyzed in established, solid tumors that had developed behind windows implanted on the backs of mice. Events could be followed repeatedly within precisely the same tumor region-before, during and after adoptive T cell therapy-thereby enabling for the first time a longitudinal in vivo evaluation of protracted events, an analysis not possible with terminal imaging of surgically exposed tumors. T cell infiltration, stromal interactions, and vessel destruction, as well as the functional consequences thereof, including the elimination of cancer cells and cancer cell variants were studied. Minimal perivascular T cell infiltrates initiated vascular destruction inside the tumor mass eventually leading to macroscopic central tumor necrosis. Prolonged engagement of T cells with tumor antigen-crosspresenting stromal cells correlated with high IFNγ cytokine release and bystander elimination of antigen-negative cancer cells. The high-resolution, longitudinal, in vivo imaging approach described here will help to further a better mechanistic understanding of tumor eradication by T cells and other anti-cancer therapies.

journal_name

Oncoimmunology

journal_title

Oncoimmunology

authors

Schietinger A,Arina A,Liu RB,Wells S,Huang J,Engels B,Bindokas V,Bartkowiak T,Lee D,Herrmann A,Piston DW,Pittet MJ,Lin PC,Zal T,Schreiber H

doi

10.4161/onci.26677

subject

Has Abstract

pub_date

2013-11-01 00:00:00

pages

e26677

issue

11

eissn

2162-4011

issn

2162-402X

pii

2013ONCOIMM0284

journal_volume

2

pub_type

杂志文章
  • Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of

    abstract::Background: VPM1002BC is a modified mycobacterium Bacillus Calmette Guérin (BCG) for the treatment of non-muscle invasive bladder cancer (NMIBC). The genetic modifications are expected to result in better immunogenicity and less side effects. We report on patient safety and immunology of the first intravesical applica...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1748981

    authors: Rentsch CA,Bosshard P,Mayor G,Rieken M,Püschel H,Wirth G,Cathomas R,Parzmair GP,Grode L,Eisele B,Sharma H,Gupta M,Gairola S,Shaligram U,Goldenberger D,Spertini F,Audran R,Enoiu M,Berardi S,Hayoz S,Wicki A

    更新日期:2020-04-21 00:00:00

  • Co-delivery of the NKT agonist α-galactosylceramide and tumor antigens to cross-priming dendritic cells breaks tolerance to self-antigens and promotes antitumor responses.

    abstract::Vaccines designed to abrogate the tolerance of tumor self-antigens and amplify cytotoxic CD8+ T cells (CTLs) have promise for the treatment of cancer. Type I natural killer (NKT) cells have attracted considerable interest in the cancer therapy field. In the current study, we have exploited the unique ability of NKT ce...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1339855

    authors: Ghinnagow R,De Meester J,Cruz LJ,Aspord C,Corgnac S,Macho-Fernandez E,Soulard D,Fontaine J,Chaperot L,Charles J,Soncin F,Mami-Chouaib F,Plumas J,Faveeuw C,Trottein F

    更新日期:2017-08-18 00:00:00

  • Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses.

    abstract::Synthesis of extracellular adenosine by the ectonucleotidases CD39 and CD73 represents an important pathway of immune suppression in the tumor microenvironment. Using two mouse models (RET transgenic melanoma and Panc02 orthotopic pancreatic adenocarcinoma), we identified an elevated frequency of ectonucleotidase-expr...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1744946

    authors: Shevchenko I,Mathes A,Groth C,Karakhanova S,Müller V,Utikal J,Werner J,Bazhin AV,Umansky V

    更新日期:2020-04-09 00:00:00

  • Hormesis in cancer immunology: Does the quantity of an immune reactant matter?

    abstract::We recently reported that tumor-directed antibodies could either stimulate, or inhibit, tumor progression, dependent upon the dosage used. The narrow range over which this immune response curve (IRC) occurs is surprising. Here we discuss features of the IRC, the mechanisms identified so far, and the potential clinical...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.29312

    authors: Pearce OM,Läubli H,Bui J,Varki A

    更新日期:2014-06-25 00:00:00

  • Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer.

    abstract::The blockade of the PD-1 pathway can increase the production of interferon γ by tumor-specific T cells located within or in the proximity of the malignant lesion, thereby increasing the chemokine-dependent trafficking of immune effector cells. This can boost the efficacy of adoptive T-cell therapy to achieve superior ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.22691

    authors: Peng W,Lizée G,Hwu P

    更新日期:2013-02-01 00:00:00

  • Development of a novel universal immune receptor for antigen targeting: To Infinity and beyond.

    abstract::Chimeric antigen receptors (CARs) possess fixed specificity for a single antigen and require empirical testing in T cells. To address this, we have developed a novel, adaptable immune receptor strategy that allows for the rapid generation and testing of T cells of nearly infinite antigen specificity. ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.19730

    authors: Urbanska K,Powell DJ

    更新日期:2012-08-01 00:00:00

  • Glycan-mediated modification of the immune response.

    abstract::Aberrantly glycosylated tumor antigens represent promising targets for the development of anti-cancer vaccines, yet how glycans influence immune responses is poorly understood. Recent studies have demonstrated that GalNAc-glycosylation enhances antigen uptake by dendritic cells as well as CD4+ T-cell and humoral respo...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.23659

    authors: Madsen CB,Pedersen AE,Wandall HH

    更新日期:2013-04-01 00:00:00

  • Targeting the C-terminus of galectin-9 induces mesothelioma apoptosis and M2 macrophage depletion.

    abstract::Galectin-9 has emerged as a promising biological target for cancer immunotherapy due to its role as a regulator of macrophage and T-cell differentiation. In addition, its expression in tumor cells modulates tumor cell adhesion, metastasis, and apoptosis. Malignant mesothelioma (MM) is an aggressive neoplasm of the mes...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2019.1601482

    authors: Bertino P,Premeaux TA,Fujita T,Haun BK,Marciel MP,Hoffmann FW,Garcia A,Yiang H,Pastorino S,Carbone M,Niki T,Berestecky J,Hoffmann PR,Ndhlovu LC

    更新日期:2019-04-17 00:00:00

  • Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy.

    abstract::Depending on tumor type, stage and immunological contexture, the inhibition of chemokines or their receptors may yield positive or deleterious effects on disease progression. We have recently demonstrated in several murine models of anthracycline-based chemotherapy that the inhibition of chemokine (C-C motif) ligand 2...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.27663

    authors: Ma Y,Adjemian S,Galluzzi L,Zitvogel L,Kroemer G

    更新日期:2014-01-01 00:00:00

  • SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer.

    abstract::Immunotherapeutic strategies including the blockade of programmed death 1 (PD-1) receptors hold promise for the treatment of various cancers including non-small cell lung carcinoma (NSCLC). Preclinical data suggest that pre-existing tumor immunity is important for disease regression upon checkpoint blockade-based ther...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.25205

    authors: Dhodapkar KM,Gettinger SN,Das R,Zebroski H,Dhodapkar MV

    更新日期:2013-07-01 00:00:00

  • Bortezomib sensitizes multiple myeloma to NK cells via ER-stress-induced suppression of HLA-E and upregulation of DR5.

    abstract::Although the proteasome inhibitor bortezomib has significantly improved the survival of patients with multiple myeloma (MM), the disease remains fatal as most patients eventually develop progressive disease. Recent data indicate that MM cells can evade bortezomib-induced cell death by undergoing autophagy as a consequ...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1534664

    authors: Carlsten M,Namazi A,Reger R,Levy E,Berg M,St Hilaire C,Childs RW

    更新日期:2018-11-02 00:00:00

  • RhoGDI2 suppresses bladder cancer metastasis via reduction of inflammation in the tumor microenvironment.

    abstract::Low expression of RhoGDI2 is associated with poor outcome in cancer patients. In animal models, RhoGDI2 suppresses lung metastasis by reducing the expression of the proteoglycan versican, whose levels portend poor patient prognosis. Versican promotes metastasis through enhanced tumor migration and creation of an infla...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.20594

    authors: Said N,Theodorescu D

    更新日期:2012-10-01 00:00:00

  • Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma.

    abstract::β-glucans are complex, naturally-occurring polysaccharides that prime leukocyte dectin and complement receptor 3. Based on our preclinical findings, indicating that oral barley-derived (1 → 3),(1 → 4)-β-D-glucan (BG) synergizes with the murine anti-GD2 antibody 3F8 against neuroblastoma, we conducted a Phase I clinica...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.23402

    authors: Modak S,Kushner BH,Kramer K,Vickers A,Cheung IY,Cheung NK

    更新日期:2013-03-01 00:00:00

  • Trial Watch: Toll-like receptor agonists for cancer therapy.

    abstract::Toll-like receptors (TLRs) have long been known for their ability to initiate innate immune responses upon exposure to conserved microbial components such as lipopolysaccharide (LPS) and double-stranded RNA. More recently, this family of pattern recognition receptors has been attributed a critical role in the elicitat...

    journal_title:Oncoimmunology

    pub_type: 评审

    doi:10.4161/onci.25238

    authors: Vacchelli E,Eggermont A,Sautès-Fridman C,Galon J,Zitvogel L,Kroemer G,Galluzzi L

    更新日期:2013-08-01 00:00:00

  • B cells in esophago-gastric adenocarcinoma are highly differentiated, organize in tertiary lymphoid structures and produce tumor-specific antibodies.

    abstract::Tumor-infiltrating lymphocytes (TILs) are correlated to prognosis of several kinds of cancer. Most studies focused on T cells, while the role of tumor-associated B cells (TABs) has only recently gained more attention. TABs contain subpopulations with distinct functions, potentially promoting or inhibiting immune respo...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1512458

    authors: Schlößer HA,Thelen M,Lechner A,Wennhold K,Garcia-Marquez MA,Rothschild SI,Staib E,Zander T,Beutner D,Gathof B,Gilles R,Cukuroglu E,Göke J,Shimabukuro-Vornhagen A,Drebber U,Quaas A,Bruns CJ,Hölscher AH,Von Bergwelt-Bai

    更新日期:2018-11-02 00:00:00

  • Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity.

    abstract::Tumor infiltrating lymphocytes (TIL) in Epstein-Barr virus (EBV)-associated/microsatellite-unstable (MSI) gastric carcinomas (GC) constitute immune-active principal cellular components of tumor microenvironment and contribute to better prognosis. With the remarkable success of cancer immunotherapies, there is an urgen...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1356150

    authors: Park C,Cho J,Lee J,Kang SY,An JY,Choi MG,Lee JH,Sohn TS,Bae JM,Kim S,Kim ST,Park SH,Park JO,Kang WK,Sohn I,Jung SH,Kang MS,Kim KM

    更新日期:2017-08-10 00:00:00

  • Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against γδ T cell cytotoxicity.

    abstract::The prostaglandin (PG) synthetase cyclooxygenase 2 (Cox-2) promotes tumorigenesis, tumor progression, and metastasis in a variety of human cancer entities including pancreatic ductal adenocarcinoma (PDAC). In this study, we demonstrate that in PDAC cells such as Colo357 cells, enhanced Cox-2 expression and increased r...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/2162402X.2014.988460

    authors: Gonnermann D,Oberg HH,Kellner C,Peipp M,Sebens S,Kabelitz D,Wesch D

    更新日期:2015-01-07 00:00:00

  • Pharmacological targeting of peptidylarginine deiminase 4 prevents cancer-associated kidney injury in mice.

    abstract::Renal insufficiency is a frequent cancer-associated problem affecting more than half of all cancer patients at the time of diagnosis. To minimize nephrotoxic effects the dosage of anticancer drugs are reduced in these patients, leading to sub-optimal treatment efficacy. Despite the severity of this cancer-associated p...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2017.1320009

    authors: Cedervall J,Dragomir A,Saupe F,Zhang Y,Ärnlöv J,Larsson E,Dimberg A,Larsson A,Olsson AK

    更新日期:2017-04-20 00:00:00

  • Immunosurveillance in esophageal carcinoma: The decisive impact of regulatory T cells.

    abstract::Neoadjuvant radiochemotherapy of esophageal carcinomas causes a variable degree of depletion of tumor-infiltrating FOXP3+ regulatory T cells (Tregs). The frequency of local Tregs in the operative specimens negatively correlates with the pathological response and overall patient survival. These results underscore the i...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1064581

    authors: Vacchelli E,Semeraro M,Adam J,Dartigues P,Zitvogel L,Kroemer G

    更新日期:2015-07-01 00:00:00

  • PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy.

    abstract::PD-1 engagement on the surface of effector T cells strongly suppresses their cytotoxic function, which constitutes a major obstacle for T cell-mediated anti-tumor activities. Surprisingly, PD-1 is strongly upregulated in T cells, engaging its ligand PD-L1 during antigen presentation. However, our recent published data...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.1.1.17824

    authors: Karwacz K,Arce F,Bricogne C,Kochan G,Escors D

    更新日期:2012-01-01 00:00:00

  • Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival.

    abstract::There is increased production of plasmacytoid dendritic cells (pDCs) in the bone marrow (BM) of multiple myeloma (MM) patients and these favor Th22 cell differentiation. Here, we found that the frequency of interleukin (IL)-22+IL-17-IL-13+ T cells is significantly increased in peripheral blood (PB) and BM of stage III...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1005460

    authors: Di Lullo G,Marcatti M,Heltai S,Brunetto E,Tresoldi C,Bondanza A,Bonini C,Ponzoni M,Tonon G,Ciceri F,Bordignon C,Protti MP

    更新日期:2015-02-03 00:00:00

  • Ecrg4 contributes to the anti-glioma immunosurveillance through type-I interferon signaling.

    abstract::Esophageal cancer-related gene 4 (Ecrg4), a hormone-like peptide, is thought to be a tumor suppressor, however, little is known about the mechanism of how Ecrg4 suppresses tumorigenesis. Here, we show that the ecrg4 null glioma-initiating cell (GIC) line, which was generated from neural stem cells of ecrg4 knockout (K...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1242547

    authors: Moriguchi T,Kaneumi S,Takeda S,Enomoto K,Mishra SK,Miki T,Koshimizu U,Kitamura H,Kondo T

    更新日期:2016-10-14 00:00:00

  • TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer.

    abstract::Advanced ovarian cancer (OC) patients have a poor 5-year survival of only 28%, emphasizing the medical need for improved therapies. Adjuvant immunotherapy could be an attractive approach since OC is an immunogenic disease and the presence of tumor-infiltrating lymphocytes has shown to positively correlate with patient...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2020.1843247

    authors: Maas RJ,Hoogstad-van Evert JS,Van der Meer JM,Mekers V,Rezaeifard S,Korman AJ,de Jonge PK,Cany J,Woestenenk R,Schaap NP,Massuger LF,Jansen JH,Hobo W,Dolstra H

    更新日期:2020-11-08 00:00:00

  • Macrophages increase the resistance of pancreatic adenocarcinoma cells to gemcitabine by upregulating cytidine deaminase.

    abstract::Tumor-associated macrophages play a central role in tumor progression and metastasis. Macrophages can also promote the resistance of malignant cells to chemotherapy by stimulating the upregulation of cytidine deaminase, an intracellular enzyme that catabolizes the active form of gemcitabine. Targeting macrophage-depen...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.27231

    authors: Amit M,Gil Z

    更新日期:2013-12-01 00:00:00

  • In Situ immunization by bispecific antibody targeted T cell therapy in breast cancer.

    abstract::Metastatic breast cancer remains an incurable disease. Most patients experience objective treatment responses associated with palliation of symptoms; however, progression inevitably occurs. Thus, there is an urgent need for innovative therapeutic strategies that may halt disease progression. Adoptive T-cell therapy is...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1055061

    authors: Thakur A,Lum LG

    更新日期:2015-07-15 00:00:00

  • The role of Foxp3 and Tbet co-expressing Treg cells in lung carcinoma.

    abstract::Despite the opposite roles of Tbet and Foxp3 in the immune system as well as in tumour biology, recent studies have demonstrated the presence of of CD4+ T cells, expressing both, Tbet and Foxp3. Although Tbet+Foxp3+ T cells are currently a subject of intense research, less is known about their biological function espe...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2018.1456612

    authors: Kachler K,Holzinger C,Trufa DI,Sirbu H,Finotto S

    更新日期:2018-04-25 00:00:00

  • Linking oncogenesis and immune system evasion in acquired resistance to EGFR-targeting antibodies: Lessons from a preclinical model.

    abstract::Searching for biomarkers that associated with the acquired resistance of malignant cells to epidermal growth factor receptor (EGFR)-targeting monoclonal antibodies is crucial to improve the clinical benefits of these therapeutic agents. We have recently demonstrated that molecular alterations in both oncogenic and imm...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.4161/onci.26904

    authors: Garrido G,Rabasa A,Sánchez B

    更新日期:2013-12-01 00:00:00

  • Zoledronate can induce colorectal cancer microenvironment expressing BTN3A1 to stimulate effector γδ T cells with antitumor activity.

    abstract::Amino-bis-phosphonates (N-BPs) such as zoledronate (Zol) have been used in anticancer clinical trials due to their ability to upregulate pyrophosphate accumulation promoting antitumor Vγ9Vδ2 T cells. The butyrophilin 3A (BTN3A, CD277) family, mainly the BTN3A1 isoform, has emerged as an important structure contributin...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2016.1278099

    authors: Zocchi MR,Costa D,Venè R,Tosetti F,Ferrari N,Minghelli S,Benelli R,Scabini S,Romairone E,Catellani S,Profumo A,Poggi A

    更新日期:2017-01-06 00:00:00

  • New role of Interleukin-10 in enhancing the antitumor efficacy of oncolytic vaccinia virus for treatment of pancreatic cancer.

    abstract::Although the profile of safety of tumor-targeted oncolytic virus (TOV) is encouraging, the antitumor efficacy of TOV alone is disappointing. Interleukin-10 (IL-10) plays an important role in carcinogenesis and anti-virus immunity. Here we report that tumor-targeted oncolytic vaccinia virus (VV) armed with IL10 shows p...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1038689

    authors: Chard LS,Lemoine NR,Wang Y

    更新日期:2015-07-20 00:00:00

  • Tumor evasion of humoral immunity mediated by proteolytic impairment of antibody triggered immune effector function.

    abstract::Immune suppression is recognized as a hallmark of cancer and this notion is largely based on studies on cellular immunity. Our recent studies have demonstrated a potential new mechanism of cancer suppression of immunity by impairment of antibody effector function mediated by proteolytic enzymes in the tumor microenvir...

    journal_title:Oncoimmunology

    pub_type: 杂志文章

    doi:10.1080/2162402X.2015.1122861

    authors: Zhang N,Jordan RE,An Z

    更新日期:2015-12-29 00:00:00